, Définitions lexicographiques et étymologiques de « stratégie » du Trésor de la langue française informatisé, 2012.
Orphan drug: Development trends and strategies, J Pharm Bioallied Sci, vol.2, issue.4, pp.290-299, 2010. ,
Niche is the new normal: the growth of the orphan drugs market, Pharmaceutical Technology, 2017. ,
Developing products for rare disease & conditions, 2018. ,
Development of medicines for rare diseases, 2018. ,
, Definition of Immunotherapy, NCI Dictionary of Cancer Terms, 2018.
, Immunothérapie : mode d'action, 2017.
, Personalized Medicine Coalition, 2015.
Summary of Product Characteristics Cryvista, 2018. ,
, Summary of Product Characteristics Bavencio, 2018.
, Les maladies monogéniques et multifactorielles, overblog, 2011.
La mucoviscidose : du gène CFTR au conseil génétique, 2011. ,
Déficit immunitaire combiné sévère par déficit en adénosine désaminase, orphanet, 2012. ,
Goodbye Glybera! The world's first gene therapy will be withdrawn, 2017. ,
, LEEM, les procedures d'enregistrement d'un medicament en Europe, Chapitre 4 la règlementation du médicament
Prime : priority medicines, 2018. ,
Orphan medicines regulation, 2009. ,
Orphan Designation : overview, 2018. ,
, Horizon 2020 -Work program 2018-2020, 8. Health, demographic, European Comission, 2018.
The current status of orphan drug development in Euope and the US Intractable Rare Dis Res, vol.3, pp.1-7, 2014. ,
Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen, Orphanet journal of rare diseases, vol.12, p.64, 2017. ,
, Recommendation for removal of orphan designation at the time of marketing authorisation -Emplicti (elotuzumab) for the treatment of multiple myeloma, EMA Committee for Orphan Medicinal Products, 2016.
Adaptive clinical trials in orphan drug development, 2012. ,
, Rare diseases: common issues in drug development, guidance for industry, 2015.
Rare diseases require unique approaches in clinical trial design, clinical leader, 2017. ,
Establishing a Reasonable Price for an Orphan Drug, 2018. ,
Characteristic of clinical trials in rare vs common diseases: A register-based Latvian study, PLoS ONE, vol.13, issue.4, p.194494, 2018. ,
Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer, JAMA, vol.305, issue.22, pp.2320-2326, 2011. ,
From promising molecules to orphan drugs: Early clinical drug development, Intractable Rare Dis Res, vol.6, pp.29-34, 2017. ,
The future of orphan drugs in Europe, GlobalData, p.1445, 2017. ,
, Fast track, breaktrhrough therapy, accelerated approval, priority review, FDA, 2018.
Estimation of clinical trial success rates and related parameters, Biostatistics, vol.00, pp.1-14, 2018. ,
Reimbursed price of orphan drugs: current strategies and potential improvements, Public Health Genomics, vol.20, pp.1-8, 2017. ,
Market access trends across the EU5: 2009 to 2016-An update, Value in health, vol.20, p.677, 2017. ,
A comparative study of orphan drug prices in Europe, Journal of Market Access & Health Policy, vol.5, issue.1, 2017. ,
De l'AMM à la fixation du prix : les spécificités des maladies rares à mieux prendre en compte, vol.19, 2016. ,
A pilot study of multicriteria decision analysis for valuing orphan medicines, Value in Health, vol.16, issue.8, pp.1163-1169, 2013. ,
, European network for Health Technology Assessment: HTA Core Model®, vol.30, 2018.
Orphan drug pricing in Europe, White paper, Health Advances and Parexel, 2017. ,
, York; York Health Economics Consortium, 2016.
A roadmap to strategic drug pricing, In Vivo the business medicine report, vol.34, 2016. ,
, Orphan drug report, 2018.
Orphan drug trends, pp.143-144, 2011. ,
What is wrong with orphan drug policies? Value Health, vol.15, pp.1185-91, 2012. ,
, The tope 10 drug launches of 2017, 2017.
, Comité économique des produits de santé, 2018.
, Lists of medicinal products for rare diseases in Europe, Orphan drugs collection, Orphanet Report Series, 2018.
, Orphan drug report 2013, 2013.
Orphan drugs, IgeaHub pharmaceutical club, 2018. ,
, Pharmaceuticals -Community register, Register of designated orphan medicinal products, European Comission, issue.2, 2018.
Do investors value the orphan drug designation?, Orphanet Journal, 2017. ,
Stratégie : Embouteillage dans l'oncologie et conséquences, 2018. ,
The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?, Health Policy, vol.95, pp.216-228, 2010. ,
Stratégique, 11ème édition, Éditions Pearson, pp.415-449, 2017. ,
Les fusions acquisitions dans l'industrie pharmaceutique, outil de croissance et de création de valeur ? Le cas Norgine, Thèses, 2014. ,
Value drivers in licensing deals, Nature Biotechnology, vol.20, issue.11, pp.1085-1094, 2002. ,
Gamida cell ppt_englih_5-5-2010, slideshare linkedin, 2014. ,
RegeneRx completes license expansion for RGN-137 in Europe, 2017. ,
RegeneRx licensee GtreeBNT enter into joint venture to globally develop RGN-137 for treatment of epidermolysis bullosa, 2018. ,
Joint venture plans to advance potential EB therapy RGN-137 into phase 3 trial, Epidermolysis Bullosa News, 2018. ,
Définition de synergie, Dictionnaire de la Langue française, pp.1872-1877 ,
We spoke to the CEO of Roche Pharmaceuticals about how the giant became a deal machine, 2018. ,
Getting struck twice: acquisitions and spinouts in biotech, 2017. ,
Acquiring orphans, Biotentrepreneur, 2014. ,
, Jazz Pharmaceutical to acquire orphan medical; combines Orphan Medical's growing central nervous system product and commercial team with jazz pharmaceutical's development pipeline, Jazz-Pharmaceuticals-Acquire-Orphan-Medical-Combines-Orphan, 2005.
, Xyrem -Jazz Pharmaceuticals, Fierce Pharma, 2016.
Alexion's deal discipline sure beats a previous disaster, Bloomberg Opinion, 2018. ,
, United Securities and Exchange Comission, SEC Fillings Forms D
What is in-liensing, Pharmaceutical Investing News, 2018. ,
Big Pharma thinks small, 2006. ,
Advanced business development course prepared for Bio's, Dillon Capital Strategies, 2015. ,
The Art of the deal -licensing trends in orphan drugs, 2014. ,
The economics of licensing contracts, Nature, 2008. ,
, Pfizer snags orphan drug in $70M licensing deal with Repligen, FierceBiotech, 2013.
Santhera obtains worldwide exclusive license from polyphor to develop and commercialize clinical stage candidate for cystic fibrosis and other pulmonary diseases, Santhera-Obtains-Worldwide-Exclusive-Licensefrom-Polyphor-to-Develop-and-Commercialize-Clinical-Stage-Candidate-for-Cystic-Fibrosis-and-Other-Pulmonary-Diseases.html, 2018. ,
Sobi strengthens inflammation franchise by acquiring global rights for emapalumab from Novimmune, Press realease, 2018. ,
Sobi to acquire Synagis US rights from AstraZenecacreates a platform for global growth, Press release, 2018. ,
Recordati acquires Orphan Europe, a European group specialized in rare diseases, 2007. ,
Australia's sigma buys Orphan for A$130 mln, 2007. ,
Control premium study 2017, insight into market dynamics, financial dynamics and other factors, 2017. ,
M&A Market, structure, volatility and acquisition premiums, Bank Zachodni WBK, p.34, 2011. ,
Start-up valuation of biotech companies with real options, 2016. ,
Pharma-Biotech company valuation -an introduction, The Valuation Experts, Fit for Health 2.0, Venture Valuation group, 2015. ,
Navigating through a biotechnology valuation, vol.8, pp.207-216, 1997. ,
Using the Monte Carlo method to value early stage, technology-based intellectual property assets, 2013. ,
Biotechnology valuation: an introductory guide, 2008. ,
Project valuation using real options: a practitioner's guide. Fort Lauderdale, 2006. ,
Realistic Investment Valuation: A Comprehensive Real Options Model, Journal of Business Management, issue.7, pp.58-71, 2013. ,
Deal structures in the life sciences industry and their financial statement implications, dissertation of the university of St Gallen, Difrodruck GmbH Bamber, p.34, 2014. ,
The Art of M&A Strategy: A Guide to Building Your Company's Future through Mergers, Acquisitions, and Divestitures, 2012. ,
L'analyse en options réelles comme méthode de valorisation de projets R&D en entreprise, Louvain school of management, 2016. ,